SureGene Receives IRS Funds, SBIR Matching Grant to Advance PGx of Antipsychotic Drugs
November 17, 2010
SureGene Receives IRS Funds, SBIR Matching Grant to Advance PGx of Antipsychotic Drugs
The company has received a $224,500 Therapeutic Discovery Project Tax Credit and a $365,579 SBIR Phase II matching grant from the Commonwealth of Kentucky to continue the development of a predictive test to guide treatment of antipsychotic drugs.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Medco, SureGene to Validate SULT4A1 Variants for Gauging Patient Response to Antipsychotic Drugs
August 25, 2010 / Pharmacogenomics Reporter - Medco to Evaluate Clinical Utility of AssureRx's PGx Test in Guiding Psychiatric Treatment
May 18, 2011 / Pharmacogenomics Reporter - AstraZeneca Extends BioWisdom Partnership as Part of New Tox-Informatics Strategy
April 17, 2009 / BioInform - Personalized Medicine in 2012: Industry Takes a Wait-and-See Approach Due to Market Unknowns
January 9, 2013 / Pharmacogenomics Reporter - Knowledge of KIF6 Mutation Status Increases Patients' Statin Adherence, Medco Study Finds
March 28, 2012 / Pharmacogenomics Reporter